GCMI team members continue to distinguish themselves through industry association or other external recognition. Very recently this was the case for our CEO Sherry Farrugia who was named to the inaugural Atlanta Business Chronicle “Power 10: Health Care list.” From the publication: “There is no shortage of exceptional health care professionals in metro Atlanta.…
Innovation in pediatric technologies that address unmet clinical needs lags behind innovation for adult populations in large part due to its relatively small market size and ROI (return on investment) prospects for industry, continuously changing anatomies of children, and limited populations for testing and clinical trials. Activity sequence and process matters a great deal…
A dive into the Georgia Research Alliance (GRA) and its funding programs with GRA VP of Venture Development Ashley Cornelison In the first of this short series on medtech innovation funding opportunities, GCMI Director of Scientific Affairs Evan Goldberg stated, “GRA is the first place to go for those trying to commercialize a technology out…
What it is and when to jump in for institutional faculty, investigators and researchers with high potential new medical technologies. The engineering expertise of Georgia Tech faculty, researchers and students, coupled with the highly robust health tech and healthcare ecosystem in Atlanta breeds novel solutions to unmet clinical needs; Scott Hollister, Omer Inan and W.…
The team’s work to date, from concept to the technology’s current state, had primed it to seize the opportunity presented by the January 2022 Centers for Medicare and Medicaid Services (CMS) announcement of five new remote therapeutic monitoring CPT codes.
“The failure of existing products on the market to successfully accomplish the needs of patients and clinicians made this a problem we addressed with enthusiasm and with the support and encouragement of Dr. Emily Blum and Dr. Jenelle Foote.”
“Our confidence in data generated by our in vivo studies with T3 Labs cannot be greater.” – Dr. Hee Cheol Cho The Preclinical Challenge Dr. Hee Cheol Cho and his team needed sufficient feasibility data from physiologically appropriate preclinical studies to pursue public funding opportunities to complete their translational research for a life changing…
Watch, listen and learn. Our 2020 AdvanSE session can help you know, and fix, the ways medtech innovators burn cash unnecessarily. Too many promising medtech innovations and early stage companies fail unnecessarily because they run out of funding before achieving milestones required for next-round investments. It is possible to know earlier in the…
A long-time customer of GCMI and T3 Labs, ALung Technologies, has recently announced that they have received FDA Emergency Use Authorization (EUA) for their Hemolung® Respiratory Assist System (RAS), the world’s first fully-integrated respiratory dialysis system. This system removes carbon dioxide directly from the blood, allowing the patient’s lungs to rest and heal while avoiding…
Gross and histopathology are very important aspects of preclinical research. They can be crucial endpoints for safety and toxicity studies. Oftentimes, they help determine whether adverse events were device related. Laboratory veterinarians that write preclinical veterinary reports rely on pathologists to help explain some in-life clinical observations. Regulatory guidance documents also require that preclinical protocols…